Our simple cost-effectiveness analysis, based on direct costs alone, suggests that using G-CSF as a primary prophylaxis for chemotherapy-induced neutropenia would be more expensive to the service provider than not using it, a similar conclusion found by others in Canada and Italy (Zagonel et al, 1994, Dranitsaris et al, 1997). Here, CSF3 is linked to neutropenia.